Annual Heart Health Checkup: What to Expect
A heart health checkup is one of the most valuable investments in long-term cardiovascular health that any adult can make — yet it is systematically underutilized, particularly among younger adults who feel healthy and therefore assume preventive evaluation is unnecessary. The logic of preventive cardiovascular screening is precisely the opposite: cardiovascular disease begins silently, progresses asymptomatically for years to decades, and typically announces itself only when a significant event — heart attack, stroke, or heart failure — occurs. By that point, substantial damage may already have been done. Regular preventive evaluation detects the risk factors that drive cardiovascular disease — hypertension, dyslipidemia, diabetes, obesity — while they are still in the treatable, reversible, or modifiable phase, enabling interventions that prevent the event rather than treating its consequences.
Understanding what a comprehensive heart health checkup includes — what measurements are taken, what laboratory tests are ordered, what the numbers mean, and what actions they should trigger — empowers patients to participate actively in their cardiovascular prevention rather than passively receiving tests whose purpose they do not understand. This article provides a detailed overview of the components of a comprehensive cardiovascular preventive evaluation, the current evidence-based screening recommendations, and how to interpret and act on the results.
Blood Pressure Measurement — The Most Important Vital Sign
Blood pressure is measured at every clinical encounter and is the single most important cardiovascular vital sign — hypertension (blood pressure 130/80 mmHg or above by 2017 ACC/AHA guidelines) is the most prevalent cardiovascular risk factor globally, present in approximately 50 percent of American adults, and the leading attributable risk factor for cardiovascular mortality worldwide. Blood pressure is measured in both arms (a difference of more than 10 to 15 mmHg between arms suggests subclavian artery stenosis or coarctation of the aorta), ideally after 5 minutes of quiet rest in a seated position, with the arm at heart level and the bladder cuff covering at least 80 percent of the arm circumference.
A single office blood pressure measurement is insufficient for hypertension diagnosis — white coat hypertension (elevated office BP with normal home BP) affects 15 to 30 percent of patients, and masked hypertension (normal office BP with elevated home or ambulatory BP) affects approximately 10 to 15 percent of patients and carries cardiovascular risk comparable to sustained hypertension. Current guidelines recommend out-of-office blood pressure measurement — home blood pressure monitoring or 24-hour ambulatory blood pressure monitoring — before initiating antihypertensive therapy, to confirm that the elevated office reading represents true hypertension. Home blood pressure monitoring involves measuring blood pressure twice in the morning and twice in the evening for a week, discarding the first day’s readings, and averaging the remainder — a home blood pressure average above 130/80 mmHg confirms hypertension.
Fasting Lipid Panel — Understanding Your Cholesterol Numbers
A fasting lipid panel measures total cholesterol, LDL cholesterol (low-density lipoprotein — the primary driver of atherosclerosis), HDL cholesterol (high-density lipoprotein — the “protective” cholesterol that transports cholesterol from arteries to the liver for removal), and triglycerides. Current ACC/AHA guidelines recommend initial lipid screening in all adults aged 20 or older, with repeat screening every 4 to 6 years in those without cardiovascular risk factors, and more frequently (annually or as clinically indicated) in those with risk factors or on lipid-lowering therapy.
The most clinically significant lipid values for cardiovascular risk assessment are LDL cholesterol and non-HDL cholesterol (total cholesterol minus HDL — a measure of all atherogenic lipoproteins). While total cholesterol above 200 mg/dL has been the traditional awareness cutpoint, LDL is the therapeutic target that drives treatment decisions. The 2018 ACC/AHA cholesterol guidelines establish LDL thresholds based on cardiovascular risk category: for primary prevention patients with 10-year risk below 7.5 percent, lifestyle modification is the primary intervention; those with 10-year risk 7.5 percent or above benefit from statin therapy; and patients with established atherosclerotic cardiovascular disease (secondary prevention) have an LDL target below 70 mg/dL, with intensification to below 55 mg/dL for very high-risk patients.
Triglycerides above 150 mg/dL (borderline high) or above 200 mg/dL (high) are associated with increased cardiovascular risk and metabolic syndrome. Severely elevated triglycerides (above 500 mg/dL) carry risk of acute pancreatitis and require specific management beyond cardiovascular risk reduction. Low HDL cholesterol (below 40 mg/dL in men, below 50 mg/dL in women) is an independent cardiovascular risk factor and contributes to metabolic syndrome. HDL is primarily raised through aerobic exercise, weight loss, alcohol moderation, and smoking cessation — there are no medications that substantially and safely raise HDL.
Blood Glucose and Diabetes Screening
Diabetes mellitus doubles to quadruples cardiovascular risk and is present in approximately 11 percent of American adults, with a further 38 percent having prediabetes — impaired fasting glucose or impaired glucose tolerance — that carries significant cardiovascular risk and risk of progression to type 2 diabetes. The USPSTF recommends blood glucose screening beginning at age 35 to 40 for most adults, earlier in those with obesity or other diabetes risk factors (physical inactivity, family history, history of gestational diabetes, polycystic ovary syndrome, or conditions associated with insulin resistance).
Screening tests include fasting plasma glucose (diabetes: 126 mg/dL or above; prediabetes: 100 to 125 mg/dL), HbA1c (diabetes: 6.5 percent or above; prediabetes: 5.7 to 6.4 percent), and 2-hour glucose after a 75g oral glucose tolerance test (diabetes: 200 mg/dL or above; prediabetes: 140 to 199 mg/dL). HbA1c is increasingly preferred for screening because it does not require fasting and reflects average glucose over 2 to 3 months rather than a single-point measurement. For patients on cardiovascular preventive programs, annual HbA1c monitoring in prediabetes patients (to track progression) and periodic reassessment in those with normal screening results (every 3 years in those with risk factors) are appropriate intervals.
Cardiovascular Risk Calculation — Putting the Numbers Together
Individual risk factor measurements take on their full clinical meaning when integrated into an overall cardiovascular risk estimate. The ACC/AHA Pooled Cohort Equations — available as a free online calculator and embedded in most electronic health records — estimate the 10-year risk of a first atherosclerotic cardiovascular event (myocardial infarction or stroke) in patients aged 40 to 79, using age, sex, race/ethnicity, total cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive treatment status, diabetes, and smoking status. The resulting percentage drives treatment recommendations for primary prevention patients.
Patients with 10-year risk below 5 percent (“low risk”) typically benefit from lifestyle optimization alone without pharmacological intervention, unless specific high-risk features (very high LDL, strong family history) suggest otherwise. Those with 10-year risk 5 to 7.5 percent (“borderline risk”) occupy a gray zone where additional risk-refining tools — coronary artery calcium (CAC) scoring, high-sensitivity C-reactive protein (hsCRP), lipoprotein(a) measurement, or ankle-brachial index — can help determine whether statin therapy is beneficial. Those with 10-year risk 7.5 percent or above (“intermediate risk”) clearly benefit from moderate-intensity statin therapy. Those with 10-year risk 10 percent or above (“high risk”) benefit from high-intensity statin therapy. For patients with established ASCVD (secondary prevention), risk calculation is not used — they are by definition high risk and benefit from intensive secondary prevention regardless of risk score.
Additional Tests in a Comprehensive Heart Checkup
Resting 12-lead ECG is not recommended as a screening test in asymptomatic low-risk adults (where its yield of actionable findings is very low and false positives cause harm through unnecessary follow-up testing), but is appropriate in patients over 40 with cardiovascular risk factors, those with symptoms suggestive of cardiac disease, and all patients before initiating certain medications (antiarrhythmics, medications that affect QT interval) or exercise programs at higher intensity. When performed, the ECG can detect prior silent myocardial infarction (Q waves), left ventricular hypertrophy from hypertension (voltage criteria, ST-T changes), pre-excitation (Wolff-Parkinson-White), conduction abnormalities, and rhythm disturbances.
Coronary artery calcium (CAC) scoring is a non-contrast CT scan that quantifies calcium deposits in coronary arteries — calcium is a marker of calcified atherosclerotic plaque, so higher CAC scores indicate greater atherosclerotic burden. CAC scoring is recommended in selected adults aged 40 to 75 with borderline or intermediate 10-year cardiovascular risk where the treatment decision is uncertain — a CAC score of 0 (“zero CAC”) indicates low atherosclerotic burden and can support deferring statin therapy, while CAC scores above 100 or above the 75th percentile for age and sex indicate higher atherosclerotic burden and support initiating statin therapy. CAC scoring exposes patients to low radiation (1 to 3 mSv) and costs approximately $100 to $200 without insurance — making it highly cost-effective for appropriate candidates where it resolves treatment uncertainty.
Body weight, BMI, and waist circumference are measured at every visit. Obesity (BMI 30 or above) is a major cardiovascular risk factor associated with hypertension, dyslipidemia, sleep apnea, type 2 diabetes, and reduced physical activity. Waist circumference (abdominal obesity: above 102 cm in men, above 88 cm in women) independently predicts cardiovascular risk beyond BMI, because visceral adiposity (fat around the abdominal organs) is metabolically more active than subcutaneous fat and drives insulin resistance, inflammation, and dyslipidemia more potently.
Kidney function testing (serum creatinine, estimated GFR, urine albumin-to-creatinine ratio) is important in cardiovascular risk evaluation because chronic kidney disease is an independent cardiovascular risk factor and also affects the safety of certain cardiovascular medications (ACE inhibitors, ARBs, SGLT2 inhibitors require monitoring; NSAIDs should be avoided). Microalbuminuria (urine albumin-to-creatinine ratio above 30 mg/g) is an early marker of both kidney disease and cardiovascular risk, present in many diabetic and hypertensive patients.
Thyroid function (TSH) should be checked periodically, particularly in women over 50 and in patients with symptoms suggesting thyroid dysfunction, because both hyperthyroidism and hypothyroidism independently affect cardiovascular risk: hyperthyroidism promotes atrial fibrillation and can cause dilated cardiomyopathy; hypothyroidism raises LDL cholesterol, promotes hypertension, and can produce diastolic dysfunction and pericardial effusions. Correcting thyroid dysfunction often meaningfully improves cardiovascular risk factor profiles.
The American Heart Association’s Know Your Numbers resources explain what each cardiovascular health metric means and what targets to aim for. The CDC heart disease prevention guidelines cover recommended screening intervals and interventions. The NHLBI cardiovascular risk factor guide provides patient-friendly explanations of each major risk factor and how to address it.
Related reading: How to Lower Heart Disease Risk | Major Risk Factors for Heart Disease | What Causes Heart Disease? | Prevention After Age 40 | Prevention After Age 50
Sources
- Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350.
- Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-e248.
- Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019;74(10):e177-e232.
- USPSTF. Screening for Prediabetes and Type 2 Diabetes: USPSTF Recommendation Statement. JAMA. 2021;326(8):736-743.
- Blaha MJ, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease. Circulation. 2016;133(9):849-858.
Family History Assessment — The Risk Factor That Tests Cannot Modify
Family history of premature cardiovascular disease is an independent cardiovascular risk factor that the standard Pooled Cohort Equations do not fully capture but that meaningfully elevates cardiovascular risk. The standard definition of positive family history is a first-degree male relative (father, brother, son) with myocardial infarction or coronary revascularization before age 55, or a first-degree female relative (mother, sister, daughter) with the same events before age 65. Early coronary events in parents or siblings signal shared genetic risk factors (familial hypercholesterolemia, metabolic predispositions), shared environmental exposures (dietary patterns, exercise habits, smoking), and potentially direct cardiovascular genetic contributions beyond the common risk factor profile.
Familial hypercholesterolemia (FH) is the most clinically important genetic cardiovascular risk condition to identify during a family history assessment. FH — caused by mutations in LDL receptor, ApoB, or PCSK9 genes, present in approximately 1 in 250 to 1 in 500 individuals — produces markedly elevated LDL cholesterol (typically 190 mg/dL or above) from birth, resulting in coronary atherosclerosis that begins in childhood and produces MI in young adults without treatment. Most FH patients are undiagnosed until an elevated cholesterol or premature MI brings the condition to attention. LDL above 190 mg/dL in an adult, or above 160 mg/dL in a child, with a family history of premature cardiovascular disease or very high cholesterol in a parent or sibling, should prompt evaluation for FH and consideration of statin therapy regardless of calculated 10-year risk score.
During a heart health checkup, patients should be prepared to report: any first-degree relatives with heart attack, stroke, coronary artery bypass surgery, or stent placement before age 65 (women) or 55 (men); any first-degree relatives with sudden unexplained death before age 50 (which may indicate inherited arrhythmia syndromes); any family history of very high cholesterol; and any relatives diagnosed with hypertrophic cardiomyopathy, long QT syndrome, Marfan syndrome, or aortic aneurysm. These findings can qualify the patient for earlier screening, more aggressive preventive therapy targets, or referral for cardiac genetics evaluation.
Lifestyle Assessment and Counseling — The Non-Pharmacological Foundation
A comprehensive heart health checkup includes systematic assessment of cardiovascular-relevant lifestyle factors, with counseling and goal-setting in domains where modification can reduce risk. The five key lifestyle domains assessed in a cardiovascular preventive visit are:
Physical activity: Current guidelines recommend at least 150 minutes per week of moderate-intensity aerobic activity (brisk walking, cycling, swimming) or 75 minutes per week of vigorous-intensity activity, plus muscle-strengthening activities 2 or more days per week. Adults who meet these targets have approximately 35 percent lower cardiovascular mortality risk than those who are physically inactive. The visit should elicit current activity patterns, assess barriers to exercise, and provide concrete, achievable short-term activity goals — walking 30 minutes on most days is a realistic starting point for most inactive adults and produces significant cardiovascular benefit.
Diet quality: A heart-healthy dietary pattern — consistent evidence supporting Mediterranean, DASH (Dietary Approaches to Stop Hypertension), and whole-food plant-based patterns — emphasizes vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil while limiting red and processed meat, refined carbohydrates, added sugars, and sodium. Rather than focusing on specific nutrients (which tend to produce food moralizing without behavior change), dietary counseling that focuses on overall dietary pattern and practical food environment factors (meal planning, cooking habits, eating environment) produces more durable improvement. Brief dietary assessment tools (validated single-page questionnaires) can be administered efficiently in office settings.
Tobacco and substance use: Smoking status (current, former, never) should be assessed at every visit, with current smokers receiving cessation counseling and pharmacotherapy referral at each encounter. The 5A framework (Ask, Advise, Assess, Assist, Arrange) provides the structure for brief office-based smoking cessation intervention. Electronic cigarette/vaping use should be specifically assessed in younger adults — e-cigarettes are not cardiovascular-neutral and are associated with elevated cardiovascular risk, particularly in combination with combustible tobacco use (“dual use”). Alcohol consumption should be quantified (drinks per week); above-moderate use (above 14 drinks/week in men, 7 drinks/week in women) is associated with cardiovascular risk including hypertension, atrial fibrillation, and cardiomyopathy, warranting counseling toward moderation.
Sleep quality and duration: Both short sleep duration (less than 6 hours per night) and long sleep duration (more than 9 hours per night) associate with increased cardiovascular risk in prospective studies. Obstructive sleep apnea (OSA) — affecting approximately 15 to 30 percent of adults, substantially underdiagnosed — is an independent hypertension, atrial fibrillation, and heart failure risk factor that should be systematically screened for in cardiovascular preventive evaluations. The STOP-BANG questionnaire (Snoring, Tired, Observed apneas, Pressure/blood pressure, BMI, Age, Neck circumference, Gender) is a validated 8-question OSA screen that takes under 1 minute to administer and identifies those warranting formal sleep study evaluation.
Psychological health: As detailed in the evidence on heart disease and mental health, depression, anxiety, and chronic stress are independent cardiovascular risk factors. Brief validated screening tools (PHQ-2 for depression, GAD-2 for anxiety) can be administered as part of a comprehensive cardiovascular preventive visit to identify patients who need more thorough mental health assessment and, when indicated, referral for treatment. Social isolation assessment (“Do you have someone you can talk to if you are having a difficult time?”) should also be incorporated given the growing evidence for social isolation as a cardiovascular risk factor.
When to See a Cardiologist — Primary Care vs Specialist Evaluation
Most cardiovascular risk assessment and primary prevention can be managed effectively by primary care providers (internists, family physicians, nurse practitioners, physician assistants) who are trained in preventive cardiology and have access to the relevant diagnostic tools. Cardiology referral is appropriate in specific circumstances where specialist expertise is needed:
- Symptoms suggestive of cardiac disease: chest pain, unexplained dyspnea, palpitations, syncope or presyncope, or exercise intolerance disproportionate to apparent fitness level
- Abnormal findings on initial evaluation: new or worsening ECG abnormalities, heart murmur of uncertain significance, markedly elevated cholesterol (LDL above 190 mg/dL) suggesting familial hypercholesterolemia
- Strong family history of early cardiovascular disease, sudden cardiac death in young relatives, or inherited cardiac conditions (cardiomyopathies, channelopathies)
- Cardiovascular risk that remains inadequately controlled despite primary care management — blood pressure or LDL not at target despite appropriate pharmacotherapy
- Planning for high-intensity athletic activity in adults over 40, where exercise stress testing may be appropriate to clear high-risk patients
- Any patient with established cardiovascular disease (known coronary artery disease, prior MI, heart failure, valvular disease, arrhythmia) who does not have an established cardiologist relationship
Preparing for Your Heart Health Checkup — What to Bring and What to Ask
A heart health visit is more productive when patients arrive prepared. The following preparation maximizes the value of the encounter:
What to bring: A complete current medication list (including over-the-counter medications, supplements, and vitamins); home blood pressure readings if you have been monitoring at home (a week of morning and evening readings is ideal); any laboratory results from other providers in the past year; a written list of cardiovascular symptoms or concerns you want to discuss; and a family history summary with names and ages of any relatives who had heart attacks, strokes, or sudden cardiac death and at what ages.
What to ask your provider:
- “What is my 10-year cardiovascular risk, and what does that mean for my treatment decisions?”
- “Are my blood pressure, cholesterol, and blood sugar at target for my risk level?”
- “Should I be on a statin? If I am on one, is my LDL at the goal for my risk level?”
- “Is my level of physical activity adequate, and are there specific targets I should be working toward?”
- “Are there any additional tests — like a coronary calcium scan or echocardiogram — that would add useful information for my risk management?”
- “Given my family history, are there any hereditary conditions I should be screened for?”
- “When should I return for the next cardiovascular preventive evaluation, and what will we reassess at that visit?”
Regular heart health checkups beginning in young adulthood — with frequency increasing as age and risk factor burden grow — provide the systematic surveillance that allows cardiovascular disease to be prevented rather than treated. The investment of time in preventive evaluation pays returns measured in years of healthy life, functioning heart muscle, and events that never happen because they were preempted by knowledge-driven action.